TLR Agonist-Nanoparticle Adjuvants via Cleavable Linkages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, such as alum, often require multiple doses and fail to induce broad antibody responses, particularly for HIV and universal influenza vaccines, and TLR7/8 agonists face challenges due to low tolerability and systemic side effects.
Innovation Solution
Development of TLR agonist-nanoparticle adjuvants where TLR agonists are conjugated to polymers through cleavable linkages, forming biodegradable nanoparticles that release the agonist sustainably, enhancing immune activation with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7/8 agonists are used as vaccine adjuvants, then immune activation is enhanced, but systemic toxicity and side effects increase
Solution Approach 1:
The patent uses nanoparticle carriers as intermediaries to deliver TLR7/8 agonists to target cells. The nanoparticles encapsulate the agonists and facilitate their selective delivery to antigen-presenting cells via endocytosis, reducing systemic exposure and toxicity while maintaining immune activation efficacy
Solution Approach 2:
The patent achieves localized delivery of TLR7/8 agonists to specific target cells (antigen-presenting cells) through nanoparticle-mediated endocytic uptake. The agonists are released specifically within endosomes of target cells, creating localized immune activation without systemic side effects
2Device complexity
If alum adjuvant is used, then vaccine formulation is simple, but multiple doses are required and broad antibody responses are not induced
Solution Approach 1:
The patent employs composite nanoparticle formulations combining biodegradable polymers (PLA, PLGA), PEGylated lipids, and TLR7/8 agonists. This composite structure provides both simplified single-dose administration and enhanced immune activation for broad antibody responses
Solution Approach 2:
The patent modifies key parameters including nanoparticle size (50-200 nm), surface charge (zeta potential -10 to +10 mV), and agonist concentration within particles to optimize immune activation while enabling single-dose protective immunity
3Power
If TLR agonist is released rapidly, then immune activation is strong, but toxicity increases
Solution Approach 1:
The patent implements periodic/controlled release of TLR agonists from nanoparticles over time. The biodegradable polymer matrix gradually degrades, releasing agonists in a sustained manner that maintains immune activation while avoiding toxic peaks
Solution Approach 2:
The patent uses preliminary targeting where nanoparticles are designed with specific surface properties (PEGylation, charge) that enable preferential uptake by antigen-presenting cells before agonist release, ensuring the activated immune cells are the correct target population
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TLR agonist-nanoparticle adjuvants improve in vivo retention, lymph node accumulation, and cellular uptake, leading to robust immune responses with minimal systemic toxicity, effectively inducing both humoral and cellular immune responses.
Implementation Method 1
the TLR agonist is released in a sustained manner, reducing undesirable toxicity
Implementation Method 2
the release rate of the agonist from the nanoparticles is accelerated by the low pH in endosomes
Implementation Method 3
The TLR agonist-polymer conjugate can self-assemble, or co-nanoprecipitate with a second polymer, to form biodegradable nanoparticles
Implementation Method 4
An antigen (immunogen) of interest may be co-precipitated with the polymers to form the nanoparticle
Data Source
AI summary
Compositions and methods are provided relating to TLR agonist nanoparticle vaccine adjuvant formulations.